High-Throughput Generation of Bipod (Fab × ScFv) Bispecific Antibodies Exploits Differential Chain Expression and Affinity Capture

Overview

Journal Sci Rep

Specialty Science

Date 2020 May 7

PMID 32372058

Citations 8

Authors

Thomas C Nesspor

Kyle Kinealy

Nicholas Mazzanti

Michael D Diem

Kevin Boye

Hunter Hoffman

Christine Springer

Justin Sprenkle

Gordon Powers

Haiyan Jiang

Sherry L La Porte

Rajkumar Ganesan

Sanjaya Singh

Adam Zwolak

Affiliations

Soon will be listed here.

Abstract

Generation of bispecific antibodies (BsAbs) having two unique Fab domains requires heterodimerization of the two heavy chains and pairing of each heavy chain with its cognate light chain. An alternative bispecific scaffold (Bipod) comprising an scFv and a Fab on a heterodimeric Fc eliminates the possibility of light chain mispairing. However, unpredictable levels of chain expression and scFv-induced aggregation can complicate purification and reduce the yield of desired Bipod. Here, we describe a high-throughput method for generation of Bipods based on protein A and CH1 domain affinity capture. This method exploits over-expression of the scFv chain to maximize heterodimer yield. Bipods purified by this method have purity suitable for cell-based functional assays and in vivo studies.

Citing Articles

JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G.

Obermajer N, Zwolak A, van de Ven K, Versmissen S, Menard K, Rogers K iScience. 2025; 28(3):111876.

PMID: 40060890 PMC: 11889666. DOI: 10.1016/j.isci.2025.111876.

Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein.

Cuypers M, Jaspers T, Clerckx J, Leekens S, Cawthorne C, Bormans G Fluids Barriers CNS. 2025; 22(1):11.

PMID: 39885527 PMC: 11783731. DOI: 10.1186/s12987-025-00624-1.

A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins.

Lacy E, Nanjunda R, Klakamp S, Kwok D, Nemeth J, Powers G Sci Rep. 2025; 15(1):3352.

PMID: 39870691 PMC: 11772844. DOI: 10.1038/s41598-024-82288-9.

Procollagen-lysine 2-oxoglutarate 5-dioxygenases are responsible for 5R-hydroxylysine modification of therapeutic T-cell bispecific monoclonal antibodies produced by Chinese hamster ovary cells.

Bauer N, Boettger M, Papadaki S, Leitner T, Klostermann S, Kettenberger H Front Bioeng Biotechnol. 2024; 12:1414408.

PMID: 39530057 PMC: 11551027. DOI: 10.3389/fbioe.2024.1414408.

Design and engineering of bispecific antibodies: insights and practical considerations.

Madsen A, Pedersen L, Kristensen P, Goletz S Front Bioeng Biotechnol. 2024; 12:1352014.

PMID: 38333084 PMC: 10850309. DOI: 10.3389/fbioe.2024.1352014.

References

Labrijn A, Janmaat M, Reichert J, Parren P . Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019; 18(8):585-608. DOI: 10.1038/s41573-019-0028-1. View

Andreev J, Thambi N, Perez Bay A, Delfino F, Martin J, Kelly M . Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. Mol Cancer Ther. 2017; 16(4):681-693. DOI: 10.1158/1535-7163.MCT-16-0658. View

Zhu Y, Paniccia A, Schulick A, Chen W, Koenig M, Byers J . Identification of CD112R as a novel checkpoint for human T cells. J Exp Med. 2016; 213(2):167-76. PMC: 4749091. DOI: 10.1084/jem.20150785. View

Yu S, Li A, Liu Q, Yuan X, Xu H, Jiao D . Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol. 2017; 10(1):155. PMC: 5607507. DOI: 10.1186/s13045-017-0522-z. View

Brinkmann U, Kontermann R . The making of bispecific antibodies. MAbs. 2017; 9(2):182-212. PMC: 5297537. DOI: 10.1080/19420862.2016.1268307. View

Saunders K . Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front Immunol. 2019; 10:1296. PMC: 6568213. DOI: 10.3389/fimmu.2019.01296. View

Wang X, Mathieu M, Brezski R . IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2017; 9(1):63-73. PMC: 5777978. DOI: 10.1007/s13238-017-0473-8. View

Ha J, Kim J, Kim Y . Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Front Immunol. 2016; 7:394. PMC: 5052280. DOI: 10.3389/fimmu.2016.00394. View

Labrijn A, Meesters J, De Goeij B, van den Bremer E, Neijssen J, van Kampen M . Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A. 2013; 110(13):5145-50. PMC: 3612680. DOI: 10.1073/pnas.1220145110. View

10.

Lewis S, Wu X, Pustilnik A, Sereno A, Huang F, Rick H . Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol. 2014; 32(2):191-8. DOI: 10.1038/nbt.2797. View

11.

Dillon M, Yin Y, Zhou J, McCarty L, Ellerman D, Slaga D . Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. MAbs. 2016; 9(2):213-230. PMC: 5297516. DOI: 10.1080/19420862.2016.1267089. View

12.

Liu Z, Leng E, Gunasekaran K, Pentony M, Shen M, Howard M . A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem. 2015; 290(12):7535-62. PMC: 4367261. DOI: 10.1074/jbc.M114.620260. View

13.

De Nardis C, Hendriks L, Poirier E, Arvinte T, Gros P, Bakker A . A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G. J Biol Chem. 2017; 292(35):14706-14717. PMC: 5582861. DOI: 10.1074/jbc.M117.793497. View

14.

Spreter Von Kreudenstein T, Lario P, Dixit S . Protein engineering and the use of molecular modeling and simulation: the case of heterodimeric Fc engineering. Methods. 2013; 65(1):77-94. DOI: 10.1016/j.ymeth.2013.10.016. View

15.

Mains P, Sibley C . The requirement of light chain for the surface deposition of the heavy chain of immunoglobulin M. J Biol Chem. 1983; 258(8):5027-33. View

16.

Grugan K, Dorn K, Jarantow S, Bushey B, Pardinas J, Laquerre S . Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs. 2016; 9(1):114-126. PMC: 5240640. DOI: 10.1080/19420862.2016.1249079. View

17.

Tustian A, Endicott C, Adams B, Mattila J, Bak H . Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. MAbs. 2016; 8(4):828-38. PMC: 4966828. DOI: 10.1080/19420862.2016.1160192. View

18.

Zwolak A, Leettola C, Tam S, Goulet D, Derebe M, Pardinas J . Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding. Sci Rep. 2017; 7(1):15521. PMC: 5686111. DOI: 10.1038/s41598-017-15748-0. View